Type 2 Diabetes - Controlling the Epidemic (Episode 4 of 4) | NEJM

In this fourth episode of “Type 2 Diabetes - Controlling the Epidemic,” a four- part
Double Take video miniseries from the New England Journal of Medicine, Drs.
Jane E.B. Reusch (University of Colorado) and E. Dale Abel (UCLA) describe old
and new drugs available for diabetes therapy and discuss their benefits and side
effects. Dr. Monica Peek (University of Chicago) and other experts reflect on the
cost barriers faced by patients with diabetes and strategies used to overcome
those challenges.
For further reading, the following articles, referenced in this video, are
available at NEJM.org, where you can also watch Quick Take video summaries
of the research articles: Weekly Icodec versus Daily Glargine U100 in Type 2
Diabetes without Previous Insulin (Rosenstock et al., in the July 27, 2023, issue; www.nejm.org/d... ),
Building a Better Insulin - Whom Will It Help? (Reusch, in the July 27, 2023,
issue; www.nejm.org/d... ), Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding
et al., in the March 18, 2021, issue; www.nejm.org/d... ), Tirzepatide Once Weekly for the Treatment
of Obesity (Jastreboff et al., in the July 21, 2022, issue; www.nejm.org/d... ), and Cardiovascular and
Renal Outcomes with Efpeglenatide in Type 2 Diabetes (Gerstein et al., in the
September 2, 2021, issue; www.nejm.org/d... ).
The New England Journal of Medicine is the world’s leading general medical
journal. Continuously published for over 200 years, NEJM publishes
peer-reviewed research along with interactive clinical content for physicians,
educators, and the global medical community at NEJM.org.
#diabetes #medicaleducation #publichealth